Vanderbilt University's Drug Discovery Program has signed its second collaborative agreement with Cambridge-based Seaside Therapeutics. This time, fragile X and autism are the diseases, and finding new compounds that could become drugs to fight those diseases is the challenge the two parties have embraced. VNC's earlier report on the work of the Drug Discovery Program under Jeff Conn, Ph.D., is here.
Wednesday, January 13, 2010
VUMC's Drug Discovery's 2nd pact with Seaside
Vanderbilt University's Drug Discovery Program has signed its second collaborative agreement with Cambridge-based Seaside Therapeutics. This time, fragile X and autism are the diseases, and finding new compounds that could become drugs to fight those diseases is the challenge the two parties have embraced. VNC's earlier report on the work of the Drug Discovery Program under Jeff Conn, Ph.D., is here.
No comments:
Post a Comment